Piper Jaffray Initiates Coverage on BioMarin Pharmaceutical (BMRN) with a Neutral; Several Barriers to Growth in '09
Tweet Send to a Friend
Piper Jaffray & Co. initiates coverage on BioMarin Pharmaceutical (Nasdaq: BMRN) with a Neutral. Price target $14.
Piper analyst says ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Piper analyst says ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
